The clinical trial “A Randomized, Controlled, Open-label, Multicenter, Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Chlorogenic Acid for Injection in the Treatment of Recurrent Grade IV Glioblastoma (GBM)” recently has obtained the ethical approval of five clinical trial centers of Peking Union Medical College Hospital, Tianjin Huanhu Hospital, Jiangsu Province Hospital, Union Medical College Hospital of Huazhong University of Science and Technology and General Hospital of Ningxia Medical University recently. The start-up of clinical trials in various centers was being actively prepared.